|
 Results of the Phase III trial involving 970 people found Gilenya,
also known as fingolimod, did not show a significant difference to
placebo on a combination of disability measures.
There are currently no approved treatments for PPMS, a disorder of
the central nervous system characterized by a steady worsening of
neurologic functioning over time. It affects around 10 percent of
the 2.3 million people diagnosed with multiple sclerosis worldwide.
Gilenya is already approved in the United States and Europe as a
treatment for multiple sclerosis. The drug is being tested in Phase
III trials as a treatment for pediatric MS and chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP).
(Reporting by Caroline Copley; Editing by Gopakumar Warrier)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
